Rilpivirine (TMC-278)

What is rilpivirine?

Rilpivirine is in a category of HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine prevents HIV from entering the nucleus of healthy T-cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.

Rilpivirine will need to be used in combination with other drugs. Clinical trials will evaluate its effect in combination with other drugs, including protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs).

Depot Formulation of Rilpivirine (TMC278) May Offer Months of Sustained Anti-HIV Activity with a Single Injection
8/29/08

Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Individuals
8/08/08

Tibotec Opens Enrollment for 2 Phase III Trials of Experimental NNRTI Rilpivirine (TMC278) in Treatment-naive Patients
- 7/22/08

Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings
2/20/08

Rilpivirine (TMC278) Causes Less Blood Lipid Elevation than Efavirenz (Sustiva
8/24/07

TMC278 Demonstrates Equally Potent and Durable Efficacy, Less Rash, Better Lipid Profile, and Fewer Nervous System Effects than Efavirenz
3/06/07

HIV and AIDS: Top News Articles   HIV and AIDS: FDA-approved Treatments  HIV and AIDS: Experimental Treatments HIV and AIDS: Library of CME Programs